AZD-9833 is a potent and orally active estrogen receptor (ER) antagonist. AZD-9833 is used for the study of ER+ HER2-advanced breast cancer[1].
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
描述 | Camizestrant (AZD-9833) is a highly potent and orally bioavailable antagonist of the estrogen receptor (ER). It is employed in the investigation of ER+ HER2-negative advanced breast cancer [1]. |
体内研究 | Camizestrant (oral administration; 0.2-50 mg/kg; 20 days) demonstrates dose-dependent anti-tumor effectiveness in xenografts of human parental MCF7 mice [1]. Camizestrant (oral administration; 0.8-40 mg/kg; 30 days) reduces tumor growth in a dose-dependent manner. It achieves nearly complete inhibition of tumor growth at doses exceeding 10 mg/kg in mice [1]. |
体外研究 | Camizestrant is sourced from example 17 of US patent US20180111931A1 [1]. |
计算器 | ||||
存储液制备 | 1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
2.10mL 0.42mL 0.21mL |
10.49mL 2.10mL 1.05mL |
20.99mL 4.20mL 2.10mL |
CAS号 | 2222844-89-3 |
分子式 | C24H28F4N6 |
分子量 | 476.513 |
别名 | AZD-9833 |
运输 | 蓝冰 |
存储条件 |
液体 -20°C:3-6个月-80°C:12个月 粉末 Keep in dark place,Sealed in dry,2-8°C |
溶解度 |
DMSO: 105 mg/mL(220.35 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO |
动物实验配方 |